Gastric Cancer Bispecific Givastomig Moves Toward Accelerated Approval Pathway

According to a recent LinkedIn post from BioSpectator Inc, partners ABL Bio and NovaBridge Biosciences (formerly I-Mab) appear to have secured U.S. FDA alignment on a potential accelerated approval pathway for givastomig (ABL111) in first-line gastric and gastroesophageal cancer. The targeted population is described as HER2-negative, CLDN18.2-positive and PD-L1-positive patients, based on encouraging phase 1b combination data.

The post indicates that the companies plan to use overall response rate as the primary endpoint for accelerated approval and aim to initiate a registrational phase 3 trial for the combination regimen as early as the fourth quarter of this year. Final trial design is expected to be refined through further discussions with the FDA.

As interpreted from the post, a positive regulatory trajectory for givastomig could strengthen ABL Bio’s and NovaBridge’s positions in the competitive CLDN18.2-targeted oncology segment, where multiple global players are advancing antibodies and bispecifics. Progress toward phase 3 and a defined accelerated approval strategy may be viewed by investors as de-risking for the asset, though ultimate commercial potential will depend on confirmatory efficacy, safety, and differentiation versus emerging rivals.

The post also suggests continued validation of CLDN18.2×4-1BB bispecific approaches and of combinations with PD-1 inhibitors such as nivolumab plus chemotherapy in gastrointestinal cancers. For stakeholders tracking Korean biotech and cross-border partnerships, movement into registrational development could signal increasing deal-making and licensing optionality if clinical outcomes remain favorable.